Row	Data			Results
				Booster	Placebo
1	1st author
2	Date of publication
3	Design of clinical trial		Randomised clinical trial
			Quasi‐randomised study
4	Follow‐up time from last vaccination (year)
5	Endemicity		High
			Intermediate
			Low
6	Participants		General population
			Healthcare workers
			Intravenous (IV) drug abusers
			Sex partners
			Others
7	Mean age (year)
8	Vaccine schedule		3‐dose
			4‐dose
9	Initial vaccine type		Recombinant vaccine (RV)
			Plasma derived vaccine (PDV)?
10	Proportion with response to initial vaccination (%)
11	Booster type		Recombinant vaccine (RV)
			Plasma derived vaccine (PDV)?
12	Booster dosage (mcg)
13	Injection site		Deltoid
			Thigh
			Gluteus
14	Injection route		IM
			ID
			SD
15	Sample size
16	Dropouts
17	Anamnestic immune response (AIR)
18	Proportion of anamnestic immune response (PAIR)
19	Before intervention (booster)		GMT (mIU/mL)
			95% CI of GMT
20	1 week after intervention (booster)		GMT (mIU/mLl)
			95% CI of GMT
21	2 weeks after booster dose (booster)		GMT (mIU/mL)
			95% CI of GMT
22	3 weeks after intervention (booster)		GMT (mIU/mL)
			95% CI of GMT
23	4 weeks after intervention (booster)		GMT (mIU/mL)
			95% CI of GMT
24	2 months after intervention (booster)		GMT (mIU/mL)
			95% CI of GMT
25	1 year after intervention (booster)		GMT (mIU/mL)
			95% CI of GMT
26	Adverse events of booster	Local	Pain
			Tenderness
			Redness
			Swelling
			Other
		Systemic	Fever
			Headache
			Malaise
			Irritability
			Rash
			Nausea
			Myalgia
			Arthralgia
			Other